{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T04:59:59Z","timestamp":1785473999340,"version":"3.56.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008131","name":"Rheinische Friedrich-Wilhelms-Universit\u00e4t Bonn","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008131","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Corallopyronin A (CorA) is a natural RNA polymerase (RNAP) inhibitor active against Gram-positive pathogens, including\n                    <jats:italic>Staphylococcus aureus<\/jats:italic>\n                    . Although spontaneous resistance to CorA occurs less frequently than to rifampicin, the genetic basis and evolutionary constraints of CorA resistance remain incompletely defined. Spontaneous mutation frequencies to CorA and rifampicin were determined by fluctuation analysis in three\n                    <jats:italic>S. aureus<\/jats:italic>\n                    strains and two coagulase-negative staphylococci (CNS). Resistant mutants were phenotypically characterized and subjected to whole-genome sequencing. Double-resistant mutants were generated under rifampicin selection. Fitness costs were assessed by direct competition assays. Mutation frequencies to CorA were consistently lower than to rifampicin across all tested strains (Rif\/CorA ratios 2.3\u20132.7). Whole-genome sequencing of 41 independently derived CorA-resistant mutants revealed resistance-associated substitutions confined to the RNAP subunits RpoB and RpoC. The mutational landscape was highly restricted, with recurrent hotspots at RpoC K334 and RpoB S1127. In coagulase-negative staphylococci (CNS), resistance remained RNAP-centred but displayed broader allelic diversity, including substitutions previously described in\n                    <jats:italic>S. aureus<\/jats:italic>\n                    but identified here for the first time in CNS species, as well as the previously undescribed RpoC D810Y substitution. Ten mutants with resistance to CorA and rifampicin retained the CorA-associated mutation and acquired additional rifampicin resistance substitutions at non-overlapping RNAP residues. CorA resistance imposed a moderate fitness cost (12\u201315%), while additional rifampicin resistance resulted in mutation-dependent increases in the fitness burden. CorA resistance in staphylococci arises at lower spontaneous frequencies than rifampicin resistance and is mediated by a constrained set of RNAP mutations. The restricted mutational landscape and associated fitness costs indicate that, under the in vitro conditions examined, CorA resistance arises through more constrained evolutionary pathways than rifampicin resistance. These findings provide a foundation for further evaluation of CorA as an RNA polymerase-targeting antimicrobial.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-64170-y","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T14:54:03Z","timestamp":1785423243000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Constrained RNA polymerase mutational pathways distinguish corallopyronin A resistance from rifampicin resistance in staphylococci"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3642-6252","authenticated-orcid":false,"given":"Jesenko","family":"Kara\u010di\u0107","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0440-2456","authenticated-orcid":false,"given":"Sabina","family":"Kara\u010di\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5972-639X","authenticated-orcid":false,"given":"Miriam","family":"Grosse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Schiefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3096-2465","authenticated-orcid":false,"given":"Kenneth","family":"Pfarr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9823-2090","authenticated-orcid":false,"given":"Tanja","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8671-3831","authenticated-orcid":false,"given":"Achim","family":"Hoerauf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2933-8473","authenticated-orcid":false,"given":"Gabriele","family":"Bierbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"64170_CR1","doi-asserted-by":"publisher","first-page":"e00808","DOI":"10.1128\/aac.00808-24","volume":"68","author":"AR Zelmer","year":"2024","unstructured":"Zelmer, A. R. et al. Osteomyelitis-relevant antibiotics at clinical concentrations show limited effectivity against acute and chronic intracellular S. aureus infections in osteocytes. Antimicrob. Agents Chemother. 68, e00808\u2013e00824 (2024).","journal-title":"Antimicrob. Agents Chemother."},{"key":"64170_CR2","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1056\/NEJMra040181","volume":"351","author":"W Zimmerli","year":"2004","unstructured":"Zimmerli, W., Trampuz, A. & Ochsner, P. E. Prosthetic-joint infections. N. Engl. J. Med. 351, 1645\u20131654 (2004).","journal-title":"N. Engl. J. Med."},{"key":"64170_CR3","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S0140-6736(04)16727-5","volume":"364","author":"DP Lew","year":"2004","unstructured":"Lew, D. P., Waldvogel, F. A. & Osteomyelitis Lancet 364, 369\u2013379 (2004).","journal-title":"Lancet"},{"key":"64170_CR4","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/ja.2014.107","volume":"67","author":"BP Goldstein","year":"2014","unstructured":"Goldstein, B. P. Resistance to rifampicin: a review. J. Antibiot. 67, 625\u2013630 (2014).","journal-title":"J. Antibiot."},{"key":"64170_CR5","doi-asserted-by":"publisher","first-page":"e00339","DOI":"10.1128\/mbio.00339-24","volume":"15","author":"S Watanabe","year":"2024","unstructured":"Watanabe, S. et al. Metabolic remodeling by RNA polymerase gene mutations is associated with reduced \u03b2-lactam susceptibility in oxacillin-susceptible MRSA. mBio 15, e00339\u2013e00324 (2024).","journal-title":"mBio"},{"key":"64170_CR6","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1128\/AAC.46.11.3381-3385.2002","volume":"46","author":"TA Wichelhaus","year":"2002","unstructured":"Wichelhaus, T. A. et al. Biological cost of rifampin resistance from the perspective of Staphylococcus aureus. Antimicrob. Agents Chemother. 46, 3381\u20133385 (2002).","journal-title":"Antimicrob. Agents Chemother."},{"key":"64170_CR7","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s12866-019-1573-9","volume":"19","author":"C Wang","year":"2019","unstructured":"Wang, C. et al. Evolution of resistance mechanisms and biological characteristics of rifampicin-resistant Staphylococcus aureus strains selected in vitro. BMC Microbiol. 19, 220 (2019).","journal-title":"BMC Microbiol."},{"key":"64170_CR8","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/1471-2180-12-240","volume":"12","author":"W Zhou","year":"2012","unstructured":"Zhou, W. et al. Molecular characterization of rifampicin-resistant Staphylococcus aureus isolates in a Chinese teaching hospital from Anhui, China. BMC Microbiol. 12, 240 (2012).","journal-title":"BMC Microbiol."},{"key":"64170_CR9","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.mib.2011.07.030","volume":"14","author":"A Srivastava","year":"2011","unstructured":"Srivastava, A. et al. New target for inhibition of bacterial RNA polymerase: \u2018switch region\u2019. Curr. Opin. Microbiol. 14, 532\u2013543 (2011).","journal-title":"Curr. Opin. Microbiol."},{"key":"64170_CR10","doi-asserted-by":"publisher","first-page":"145","DOI":"10.7164\/antibiotics.38.145","volume":"38","author":"H Irschik","year":"1985","unstructured":"Irschik, H., Jansen, R., H\u00f6fle, G., Gerth, K. & Reichenbach, H. The corallopyronins, new inhibitors of bacterial RNA synthesis from Myxobacteria. J. Antibiot. 38, 145\u2013152 (1985).","journal-title":"J. Antibiot."},{"key":"64170_CR11","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.cell.2008.09.033","volume":"135","author":"J Mukhopadhyay","year":"2008","unstructured":"Mukhopadhyay, J. et al. The RNA polymerase switch region is a target for inhibitors. Cell 135, 295\u2013307 (2008).","journal-title":"Cell"},{"key":"64170_CR12","doi-asserted-by":"publisher","first-page":"943","DOI":"10.3389\/fmicb.2019.00943","volume":"10","author":"N Loeper","year":"2019","unstructured":"Loeper, N. et al. Elaborations on Corallopyronin A as a novel treatment strategy against genital chlamydial infections. Front. Microbiol. 10, 943 (2019).","journal-title":"Front. Microbiol."},{"key":"64170_CR13","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1093\/infdis\/jis341","volume":"206","author":"A Schiefer","year":"2012","unstructured":"Schiefer, A. et al. Corallopyronin A specifically targets and depletes essential obligate Wolbachia endobacteria from filarial nematodes in vivo. J. Infect. Dis. 206, 249\u2013257 (2012).","journal-title":"J. Infect. Dis."},{"key":"64170_CR14","doi-asserted-by":"publisher","first-page":"e0008930","DOI":"10.1371\/journal.pntd.0008930","volume":"14","author":"A Schiefer","year":"2020","unstructured":"Schiefer, A. et al. Corallopyronin A for short-course anti-wolbachial, macrofilaricidal treatment of filarial infections. PLoS Negl. Trop. Dis. 14, e0008930 (2020).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"64170_CR15","doi-asserted-by":"crossref","unstructured":"Balansky, J. et al. The RNA polymerase inhibitor corallopyronin a has a lower frequency of resistance than rifampicin in Staphylococcus aureus. Antibiotics 11, 920 (2022).","DOI":"10.3390\/antibiotics11070920"},{"key":"64170_CR16","doi-asserted-by":"crossref","unstructured":"Edwards, J. L. et al. Potent In Vitro and Ex Vivo Anti-Gonococcal Activity of the RpoB Inhibitor Corallopyronin A. mSphere 7, e0036222 (2022).","DOI":"10.1128\/msphere.00362-22"},{"key":"64170_CR17","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1039\/D2NP00012A","volume":"39","author":"AK Krome","year":"2022","unstructured":"Krome, A. K. et al. Corallopyronin A: antimicrobial discovery to preclinical development. Nat. Prod. Rep. 39, 1705\u20131720 (2022).","journal-title":"Nat. Prod. Rep."},{"key":"64170_CR18","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.ymben.2019.07.010","volume":"55","author":"D Pogorevc","year":"2019","unstructured":"Pogorevc, D. et al. Production optimization and biosynthesis revision of corallopyronin A, a potent anti-filarial antibiotic. Metab. Eng. 55, 201\u2013211 (2019).","journal-title":"Metab. Eng."},{"key":"64170_CR19","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1128\/AAC.44.11.3163-3166.2000","volume":"44","author":"A O\u2019Neill","year":"2000","unstructured":"O\u2019Neill, A. et al. RNA polymerase inhibitors with activity against rifampin-resistant mutants of Staphylococcus aureus. Antimicrob. Agents Chemother. 44, 3163\u20133166 (2000).","journal-title":"Antimicrob. Agents Chemother."},{"key":"64170_CR20","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1021\/acs.jnatprod.5b00175","volume":"78","author":"TF Sch\u00e4berle","year":"2015","unstructured":"Sch\u00e4berle, T. F. et al. Insights into structure\u2013activity relationships of bacterial RNA polymerase inhibiting corallopyronin derivatives. J. Nat. Prod. 78, 2505\u20132509 (2015).","journal-title":"J. Nat. Prod."},{"key":"64170_CR21","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/nature07510","volume":"457","author":"GA Belogurov","year":"2009","unstructured":"Belogurov, G. A. et al. Transcription inactivation through local refolding of the RNA polymerase structure. Nature 457, 332\u2013335 (2009).","journal-title":"Nature"},{"key":"64170_CR22","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/S0140-6736(06)68231-7","volume":"367","author":"BA Diep","year":"2006","unstructured":"Diep, B. A. et al. Complete genome sequence of USA300, an epidemic clone of community-acquired meticillin-resistant Staphylococcus aureus. Lancet 367, 731\u2013739 (2006).","journal-title":"Lancet"},{"key":"64170_CR23","doi-asserted-by":"crossref","unstructured":"Fraunholz, M. et al. Complete genome sequence of Staphylococcus aureus 6850, a highly cytotoxic and clinically virulent methicillin-sensitive strain with distant relatedness to prototype strains. Genome Announc 1, 1110\u20131128 (2013).","DOI":"10.1128\/genomeA.00775-13"},{"key":"64170_CR24","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/S0140-6736(00)04403-2","volume":"357","author":"M Kuroda","year":"2001","unstructured":"Kuroda, M. et al. Whole genome sequencing of meticillin-resistant Staphylococcus aureus. Lancet 357, 1225\u20131240 (2001).","journal-title":"Lancet"},{"key":"64170_CR25","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1128\/IAI.00088-10","volume":"78","author":"S Herbert","year":"2010","unstructured":"Herbert, S. et al. Repair of global regulators in Staphylococcus aureus 8325 and comparative analysis with other clinical isolates. Infect. Immun. 78, 2877\u20132889 (2010).","journal-title":"Infect. Immun."},{"key":"64170_CR26","doi-asserted-by":"crossref","unstructured":"Kara\u010di\u0107, J. et al. Corallopyronin A exhibits potent activity against staphylococci including MRSA and isolates from prosthetic infections. Infection 54 (3), 1369\u20131381 (2026).","DOI":"10.1007\/s15010-026-02760-8"},{"key":"64170_CR27","doi-asserted-by":"publisher","first-page":"6250","DOI":"10.1128\/AAC.01060-12","volume":"56","author":"A Srivastava","year":"2012","unstructured":"Srivastava, A., Degen, D., Ebright, Y. W. & Ebright, R. H. Frequency, spectrum, and nonzero fitness costs of resistance to myxopyronin in Staphylococcus aureus. Antimicrob. Agents Chemother. 56, 6250\u20136255 (2012).","journal-title":"Antimicrob. Agents Chemother."},{"key":"64170_CR28","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1128\/AAC.50.1.298-309.2006","volume":"50","author":"AJ O\u2019Neill","year":"2006","unstructured":"O\u2019Neill, A. J., Huovinen, T., Fishwick, C. W. G. & Chopra, I. Molecular genetic and structural modeling studies of Staphylococcus aureus RNA polymerase and the fitness of rifampin resistance genotypes in relation to clinical prevalence. Antimicrob. Agents Chemother. 50, 298\u2013309 (2006).","journal-title":"Antimicrob. Agents Chemother."},{"key":"64170_CR29","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1128\/AAC.01742-10","volume":"55","author":"K Mariner","year":"2011","unstructured":"Mariner, K. et al. Activity of and development of resistance to corallopyronin A, an inhibitor of RNA polymerase. Antimicrob. Agents Chemother. 55, 2413\u20132416 (2011).","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-64170-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-64170-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-64170-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T04:31:14Z","timestamp":1785472274000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-64170-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["64170"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-64170-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"assertion":[{"value":"7 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"23649"}}